文献速递乳腺癌放疗

预测新辅助化疗后乳房切除乳腺癌患者局部区域复发风险的新列线图

A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy.
PubMed 文献 · Radiother Oncol · 2021-06-10

该回顾性研究基于中国12家三甲医院2000–2014年间2368例接受新辅助化疗(NAC)及乳房切除的乳腺癌患者,构建并验证了预测局部区域复发(LRR)的列线图。列线图纳入年龄、ypT分期、ypN分期、淋巴结比率、乳房切除术后放疗和内分泌治疗六个因素,在训练集和验证集中的预测区分度均优于cTNM分期、ypTNM分期和Neo-Bioscore模型。

要点

  • 列线图纳入年龄、ypT、ypN、淋巴结比率、术后放疗、内分泌治疗6个因素。
  • 训练集AUC 0.792,验证集AUC 0.705,均高于cTNM、ypTNM及Neo-Bioscore。
  • 校准曲线显示列线图预测与实际观察一致性良好。

核心结论

  • 该新列线图对接受NAC及乳房切除的乳腺癌患者LRR的预测较cTNM分期、ypTNM分期和Neo-Bioscore模型更准确。

研究设计与样本

  • 回顾性分析2000至2014年中国12家三甲医院2368例接受NAC及乳房切除的乳腺癌患者。
  • 训练集为3家肿瘤医院1629例,验证集为其他9家综合医院739例。
  • 采用Fine and Gray竞争风险分析筛选因素建立列线图,并以tAUC、校准曲线和DCA评估性能。

主要发现

  • 多因素分析纳入年龄、ypT分期、ypN分期、淋巴结比率、乳房切除术后放疗和内分泌治疗共6个风险因素。
  • 训练集列线图AUC为0.792,高于cTNM的0.582、ypTNM的0.737和Neo-Bioscore的0.658。
  • 验证集列线图AUC为0.705,高于cTNM的0.619、ypTNM的0.636和Neo-Bioscore的0.584。
  • 训练集和验证集的校准曲线均显示列线图预测与实际观察一致性良好。

临床怎么用

  • 可基于年龄、ypT、ypN、淋巴结比率、术后放疗和内分泌治疗6个因素个体化评估LRR风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to establish a nomogram for predicting locoregional recurrence (LRR) in breast cancer patients treated with neoadjuvant chemotherapy (NAC) and mastectomy. METHODS: A total of 2368 patients who received NAC and mastectomy between 2000 and 2014 from 12 grade A tertiary hospitals in China were analyzed retrospectively. The nomogram was developed based on the patients treated in three cancer hospitals (training set, n = 1629) and validated based on patients from the other nine general hospitals (validation set, n = 739). Factors identified from Fine and Gray's competing risk analysis were used to establish the nomogram. The predictive performance of the nomogram model was compared with the cTNM stage, ypTNM stage, and the Neo-Bioscore model by using the area under the time dependent receiver operating characteristic curves (tAUC), calibration curve, and decision curve analysis (DCA). RESULTS: The nomogram incorporated six risk factors derived from multivariable analysis of the training set including age, ypT stage, ypN stage, lymph node ratio, postmastectomy radiotherapy, and endocrine therapy. In the training set, the AUC of the nomogram was 0.792, which was higher than the values of the cTNM stage (0.582), ypTNM stage (0.737), and the Neo-Bioscore prognosis model (0.658). In the validation set, the AUC of the cTNM (0.619); ypTNM (0.636); and Neo-Bioscore staging system (0.584) were also significantly lower than the AUC of the nomogram (0.705). Both in the training and validation sets, the calibration curve showed good agreement between the nomogram-based predictions and the actual observations. CONCLUSION: The novel nomogram provides a more accurate evaluation of LRR for breast cancer patients treated with NAC and mastectomy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang Z, Shi M, Wang WH, et al. A novel nomogram for predicting locoregional recurrence risk in breast cancer patients treated with neoadjuvant chemotherapy and mastectomy. Radiother Oncol. 2021. PMID: 34119586. doi:10.1016/j.radonc.2021.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。